News |  Disclaimer |  Contact |  Sitemap |  Privacy Notice | 
About us  |   Business Development  |   Territories  |   Partners  |  
Ewopharma partners with Biogen to commercialise BENEPALI® and FLIXABI® in Central Eastern Europe


A distribution agreement has been signed between Ewopharma and Biogen, one of the world’s oldest independent biotechnology companies, to market and sell the company’s anti-Tumor Necrosis Factor (anti-TNF) biosimilars. Starting in 2017, Ewopharma will bring BENEPALI® (etancercept) and FLIXABI® (infliximab) to six countries, Romania, Bulgaria, Croatia, Estonia, Latvia and Lithuania. BENEPALI and FLIXABI are indicated to treat a number of inflammatory diseases, including Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis and Inflammatory Bowel Disease.

To read the full press release, please click here.